research use only
Cat.No.S4327
|
In vitro |
Ethanol : 12 mg/mL
DMSO
: Insoluble
Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 377.52 | Formula | C24H31N3O |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 22881-35-2 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | Geodowin, FA, Famprofazonum | Smiles | CC(C)C1=C(N(N(C1=O)C2=CC=CC=C2)C)CN(C)C(C)CC3=CC=CC=C3 | ||
| In vitro |
Famprofazone has been known to produce methamphetamine as an active metabolite, with 15-20% of an oral dose being converted to it. This compound has occasionally been implicated in causing false positives on drug tests for amphetamines. |
References |
|---|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05940766 | Not yet recruiting | Pediatric Oncology Patients With Risk for Infections |
Insel Gruppe AG University Hospital Bern|ETH Zurich |
October 1 2024 | Not Applicable |
| NCT05689359 | Withdrawn | Breast Cancer|Gynecologic Cancer|Early-stage Breast Cancer|Peripheral Neuropathy|Chemotherapy-induced Peripheral Neuropathy |
University of Arizona |
June 2024 | Phase 2 |
| NCT06078384 | Not yet recruiting | Triple-negative Breast Cancer |
UNICANCER|MSD France|Vall d''Hebron Institute of Oncology|SOLTI Breast Cancer Research Group |
June 30 2024 | Phase 2 |
| NCT06308718 | Not yet recruiting | Krabbe Disease |
Forge Biologics Inc |
June 2024 | -- |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.